Following its Annual General Shareholders' Meeting on May 22, 2026, precision medicine and scientific instrumentation specialist Kim Forest Enterprise (金萬林-創) elected its founder and group president, Dr. Linda Chen (陳惠娥), to resume her role as Chairman of the Board. Dr. Chen declared that the enterprise will aggressively scale its dual-core framework—"Precision Health" and "Personalized Medicine"—by accelerating the clinical translation of multi-omics data models integrated with AI analysis pipelines.

• Ecosystem Milestones and the "Flywheel" Architecture: Over its 21-year corporate history, Kim Forest Enterprise has compiled massive datasets across genomics, proteomics, metabolomics, and gut microbiota dynamics. Operating through its specialized subsidiaries, EssenseAI (元萃數據) and the EssenseAI Clinic (元萃診所), the group has structured an integrated platform linking Diagnostics $rightarrow$ Big Data $rightarrow$ Predictive AI $rightarrow$ Clinical Management.
• Strategic Brand Partnerships: In April 2026, Kim Forest Enterprise secured the exclusive Taiwanese distribution rights for Olink, the global gold standard platform for high-throughput proteomics. This asset has been coupled with EssenseAI's proprietary computational engines to create a coupled Multi-Omics AI platform. Furthermore, the grand opening of the EssenseAI Clinic on May 28, 2026, completes the group's closed-loop clinical precision health ecosystem.
• The Three Primary Forward Growth Engines:
  As Taiwan transitions into a super-aged demographic profile and the National Health Insurance (NHI) program progressively expands reimbursement coverage for companion diagnostic next-generation sequencing (NGS), Kim Forest Enterprise will deploy its capital across three vectors:
1. High-Tier Multi-Omics Diagnostic Ramping: Capturing clinical demand from top-tier academic medical centers, research institutions, and multinational biopharma developers by scaling advanced sequencing pipelines, including Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), targeted NGS, proteomics, and metabolomics for oncology companion diagnostic programs.
2. AI Precision Corporate Health Management: Leveraging the newly operational EssenseAI Clinic to penetrate premium corporate check-up networks and personalized longevity programs, embedding multi-omics AI metrics directly into preventative care pathways.
3. Global Multi-Omics Enterprise Expansion: Deepening strategic commercialization alliances with international industry leaders such as Illumina and Geneyx to license its clinical AI multi-omics platform into overseas markets, scaling international brand equity.

Resource: 創辦人陳惠娥回任董事長，金萬林三引擎打造下個十年成長曲線